Loading…
Repligen Corporation is projected to rise to $187.83 by 2027, a +31% move from its current price of $143.60. RGEN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $139.50 | $143.69 | $148.00 | +0.06% |
| Aug 2 | $137.88 | $143.77 | $149.92 | +0.12% |
| Aug 3 | $136.67 | $143.86 | $151.43 | +0.18% |
| Aug 4 | $135.68 | $143.95 | $152.73 | +0.24% |
| Aug 5 | $134.81 | $144.04 | $153.89 | +0.30% |
| Aug 6 | $134.04 | $144.12 | $154.96 | +0.36% |
| Aug 7 | $133.35 | $144.21 | $155.96 | +0.43% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $133.35 | $144.21 | $155.96 | +0.43% |
| Week 2 | $129.64 | $144.83 | $161.79 | +0.85% |
| Week 3 | $127.00 | $145.44 | $166.57 | +1.28% |
| Week 4 | $124.89 | $146.06 | $170.83 | +1.71% |
| Week 5 | $123.12 | $146.68 | $174.76 | +2.15% |
| Week 6 | $121.60 | $147.31 | $178.46 | +2.58% |
| Week 7 | $120.25 | $147.94 | $181.99 | +3.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company serves life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Incorporated in 1981 and headquartered in Waltham, Massachusetts.
Its broad portfolio includes hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer, and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. The company also offers Protein A ligands and chromatography products such as OPUS pre-packed chromatography columns, ELISA test kits, and filtration products like XCell ATF Cell Retention Systems; TangenX flat sheet cassettes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths along with process analytics products such as slope spectroscopy systems.
Repligen markets its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands.
The Healthcare category placement reflects its sector.
Repligen Corporation (RGEN) is currently priced at $145.34 with a market capitalization of $7.11B and a market rank of 1087. These figures place it among mid-cap healthcare names with a global commercial footprint in bioprocessing tools and analytics.
The 30-day technical picture shows a neutral to slightly constructive setup in the near term. The thirty-day range runs from $118.68 to $177.98, with a current price of $145.34. Key levels include support at $126.37 and resistance at $148.55.
The RSI sits around 60, with the stock trading above both the 50-day simple moving average ($131.47) and the 200-day simple moving average ($139.84). Annualized volatility is elevated at 60%, indicating notable price movement potential over the near term.
Looking at the forecast, the 2026 average price is $145.34 with a min of $102.87 and a max of $211.92, and a neutral sentiment. The outlook brightens meaningfully from 2027 onward, with bullish sentiment and rising average prices through 2035 and beyond, culminating in an average of $1,579.83 by 2050 and an estimated ROI of 987%. The path includes intermediate milestones such as 2030 with an average of $256.99 and 2040 at $775.33, reflecting substantial upside across the multi-year horizon.
A major floor 28.4% below — a decisive break under it would weaken the trend.
The nearest floor, 12.0% below — buyers have tended to step in here.
The nearest ceiling, 3.4% above — a clean break opens room to run.
A major ceiling 12.6% above — clearing it would confirm fresh momentum.
Key RGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $138.64 | Buy | $140.94 | Buy |
| MA 10 | $140.06 | Buy | $140.64 | Buy |
| MA 20 | $141.93 | Buy | $140.03 | Buy |
| MA 50 | $133.03 | Buy | $135.21 | Buy |
| MA 100 | $125.76 | Buy | $132.95 | Buy |
| MA 200 | $139.80 | Buy | $134.36 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.94 | Neutral |
| Stoch RSI (14) | 55.72 | Neutral |
| CCI (20) | 28.12 | Neutral |
| Williams %R (14) | -28.30 | Info |
| MACD (12,26,9) | -0.77 | Sell |
| ROC (12) | -2.40 | Sell |
| Bollinger %B (20,2) | 0.59 | Neutral |
| Stochastic %K (14) | 71.70 | Neutral |
| TRIX (15) | 0.27 | Buy |
| Awesome (5,34) | -0.38 | Sell |
| Ultimate (7,14,28) | 56.35 | Neutral |
| Momentum (10) | -4.95 | Sell |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 141.81 | Buy |
| ADX (14) | 17.04 | Neutral |
| ATR (14) | 3.66 | Info |
The near-term technical picture remains bullish to neutral, with a current RSI of 60 and price above the key moving averages (SMA50 at $131.47 and SMA200 at $139.84). This suggests modest upside potential while momentum is not extreme. Support sits at $126.37 and resistance at $148.55, positioning the stock to push higher if buyers regain momentum.
The 30-day range of $118.68 to $177.98 indicates a broad trading band and suggests notable price flexibility over the coming weeks. The stock’s volatility is high, with annualized volatility reported at 60%, underscoring potential rapid moves in either direction.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $102.87 | $143.60 | $208.12 | 0% | Neutral | |
| $148.64 | $187.83 | $251.64 | +31% | Bullish | |
| $165.97 | $216.31 | $301.70 | +51% | Bullish | |
| $172.89 | $231.16 | $332.65 | +61% | Bullish | |
| $185.98 | $254.34 | $375.70 | +77% | Bullish | |
| $209.18 | $292.00 | $441.27 | +103% | Bullish | |
| $255.14 | $363.05 | $559.93 | +153% | Bullish | |
| $294.76 | $427.05 | $670.87 | +197% | Bullish | |
| $302.10 | $445.25 | $711.39 | +210% | Bullish | |
| $308.99 | $462.94 | $751.34 | +222% | Bullish | |
| $470.53 | $759.68 | $1,316.42 | +429% | Bullish | |
| $843.42 | $1,550.77 | $2,954.88 | +980% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $102.87 | $143.60 | $167.78 | +0.00% |
| August 2026 | $128.23 | $150.76 | $181.58 | +4.98% |
| September 2026 | $127.93 | $151.78 | $185.47 | +0.68% |
| October 2026 | $129.14 | $154.34 | $190.76 | +1.69% |
| November 2026 | $134.81 | $162.08 | $202.18 | +5.01% |
| December 2026 | $136.86 | $165.45 | $208.12 | +2.08% |
Click any year to see its month-by-month RGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The RGEN price prediction for 2026 points to an average of $143.60 (low $102.87, high $208.12) — a potential gain of 0% on today's $143.60. A consolidation phase looks the most probable path here.
In 2027, RGEN is projected to trade between $148.64 and $251.64, averaging $187.83 — a potential gain of +31% from today's $143.60. That is up +31% on the projected 2026 average. Momentum favours further upside here.
Repligen Corporation's 2028 outlook centres on $216.31, within a $165.97 to $301.70 range. That is up +15% on the projected 2027 average. That marks a +51% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, RGEN could reach as high as $332.65, with a base case around $231.16 and support toward $172.89 — roughly +61% from $143.60. Momentum favours further upside here.
Expect RGEN to range from $185.98 to $375.70 through 2030. The $254.34 average target implies a +77% move from current prices. That is up +10% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The RGEN price prediction for 2031 points to an average of $292.00 (low $209.18, high $441.27) — a potential gain of +103% on today's $143.60. Momentum favours further upside here.
In 2032, RGEN is projected to trade between $255.14 and $559.93, averaging $363.05 — a potential gain of +153% from today's $143.60. That is up +24% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Repligen Corporation's 2033 outlook centres on $427.05, within a $294.76 to $670.87 range. That is up +18% on the projected 2032 average. That marks a +197% change versus current levels. Momentum favours further upside here.
By 2034, RGEN could reach as high as $711.39, with a base case around $445.25 and support toward $302.10 — roughly +210% from $143.60. Buyers look set to stay in control over this stretch.
Expect RGEN to range from $308.99 to $751.34 through 2035. The $462.94 average target implies a +222% move from current prices. That is up +4% on the projected 2034 average. Momentum favours further upside here.
The RGEN price prediction for 2040 points to an average of $759.68 (low $470.53, high $1,316.42) — a potential gain of +429% on today's $143.60. Buyers look set to stay in control over this stretch.
In 2050, RGEN is projected to trade between $843.42 and $2,954.88, averaging $1,550.77 — a potential gain of +980% from today's $143.60. That is up +104% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RGEN today (≈ 6.963788 RGEN) could be worth
$10,799.2
+$9,799.2 (+980%) by 2050 · US Dollar
Based on the average projected RGEN price of $1,550.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RGENwould be worth at today's price.
$1,000 invested in RGEN on Jul 30, 2025 (≈ 8.140008 RGEN) would be worth
$1,168.91
+$168.91 (+16.9%) today · 1.17× · US Dollar
Based on a RGEN entry price of $122.85 vs. today's $143.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $137.6 | $1,043.6 | +4.4% |
| 1 month ago | $136.44 | $1,052.48 | +5.2% |
| 3 months ago | $117.2 | $1,225.26 | +22.5% |
| 6 months ago | $149.37 | $961.37 | -3.9% |
| 1 year ago | $122.85 | $1,168.91 | +16.9% |
| All time (5.0y) ago | $247.87 | $579.34 | -42.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RGEN forecast.
Our base-case forecast reaches $290.00 around 2031.
Implied market cap at $290.00: $16.37B
The multi-year forecast shows a bullish trajectory beginning in 2027, with rising average prices and expanding ROI well beyond the current level. In 2027 the avg is $190.40 with ROI 31 and bullish sentiment, climbing through 2028 ($220.24, ROI 51.5), 2029 ($233.77, ROI 60.9), and 2030 ($256.99, ROI 76.8) as the base expands. By 2031 the average reaches $296.70 (ROI 104.1), and 2032 $369.11 (ROI 154); 2033 $435.66 (ROI 199.8); 2034 $453.82 (ROI 212.3); 2035 $468.57 (ROI 222.4).
The horizon widens further, with 2040 showing an average of $775.33 and ROI of 433.5, and culminating in 2050 with an average of $1,579.83 and ROI of 987. These figures imply substantial upside if the forecast plays out, but they are estimates and not guarantees. Investors should consider the inherent uncertainty and the potential for volatility over such a long horizon.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $256.99 with an estimated ROI of 76.8% (min $186.53, max $382.81) and bullish sentiment.
The forecast turns bullish from 2027 onward, with an average price rising to $1,579.83 by 2050 and ROI up to 987%, though 2026 starts neutral. These are estimates and not guarantees.
Yes. The forecast shows $1,579.83 as the 2050 average, with 2040 at $775.33. By 2050, the average exceeds $1,000, indicating substantial upside in the long term (not a guarantee).
The current price is $145.34 and the market cap is $7.11B, with a rank of 1087.
RSI14 is 60. The stock trades above SMA50 ($131.47) and SMA200 ($139.84). Support is at $126.37 and resistance at $148.55. The thirty-day range is $118.68 to $177.98, and annualized volatility is 60%.
Repligen Corporation Community Discussion
0Share your Repligen Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.